One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Platinum Hall of Fame
doi : 10.1016/j.eururo.2022.11.009
Volume 83, Issue 1, January 2023, Pages e1-e10
Can Oncogenic Driver Alterations be Responsible for the Lack of Immunotherapy Efficacy in First-line Advanced Urothelial Carcinoma?
Adi Kartolo, Andrew Robinson, Francisco E. Vera Badillo
doi : 10.1016/j.eururo.2022.04.022
Volume 83, Issue 1, January 2023, Pages 1-2
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel
Umberto Capitanio a,b,*, Jens Bedke c,d , Laurence Albiges e , Alessandro Volpe f , Rachel H. Giles g , Milan Hora h , Lorenzo Marconi i , Tobias Klatte j , Yasmin Abu-Ghanem k , Saeed Dabestani l , Sergio Ferna �ndez Pello m , Fabian Hofmann n , Teele Kuusk o , Rana Tahbaz p , Thomas Powles q , Bo ̈rje Ljungberg r , Axel Bex
doi : 10.1016/j.eururo.2022.09.026
Volume 83, Issue 1, January 2023, Pages 3-5
More Accurate Imaging Is Not Stage Migration: Time To Move from “Hubble� to “Webb� in Hormone-sensitive Prostate Cancer
Narjess Ayati a , Ken Herrmann b,c , Stefano Fanti d , Declan G. Murphy e,f , Michael S. Hofman
doi : 10.1016/j.eururo.2022.10.005
Volume 83, Issue 1, January 2023, Pages 6-9
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma
Jens Bedke a,b , Laurence Albiges c , Umberto Capitanio d,e , Rachel H. Giles f , Milan Hora g , Bo ̈rje Ljungberg h , Lorenzo Marconi i , Tobias Klatte j , Alessandro Volpe k , Yasmin Abu-Ghanem l , Saeed Dabestani m , Sergio Ferna �ndez-Pello n , Fabian Hofmann o , Teele Kuusk p , Rana Tahbaz j , Thomas Powles q , Axel Bex
doi : 10.1016/j.eururo.2022.10.010
Volume 83, Issue 1, January 2023, Pages 10-14
In KEYNOTE-564, adjuvant pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) in localised clear-cell renal cell carcinoma (ccRCC) with a high risk of relapse.
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Evan Y. Yu a,*, Josep M. Piulats b , Gwenaelle Gravis c , Peter C.C. Fong d,e , Tilman Todenho ̈fer f , Brigitte Laguerre g , Jose A. Arranz h , Stephane Oudard i , Christophe Massard j,k , Julia Heinzelbecker l,m , Luke T. Nordquist n , Joan Carles o , Michael P. Kolinsky p , Marinela Augustin q , Howard Gurney r , Ali Tafreshi s , Xin Tong Li t , Ping Qiu t , Christian H. Poehlein t , Charles Schloss t , Johann S. de Bono u
doi : 10.1016/j.eururo.2022.08.005
Volume 83, Issue 1, January 2023, Pages 15-26
Pembrolizumab and olaparib have shown single-agent activity in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC).
Following the Narrow Path
Noel W. Clarke
doi : 10.1016/j.eururo.2022.09.027
Volume 83, Issue 1, January 2023, Pages 27-28
Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer
Hong Truong a , Kelsey Breen b , Subhiksha Nandakumar c , Daniel D. Sjoberg d , Yelena Kemel e , Nikita Mehta f , Andrew T. Lenis a , Peter A. Reisz a , Jessica Carruthers a , Nicole Benfante a , Vijai Joseph e , Aliya Khurram f , Anuradha Gopalan g , Samson W. Fine g , Victor E. Reuter g , Andrew J. Vickers d , Ozge Birsoy e,g , Ying Liu b , Michael Walsh b,e,h , Alicia Latham b , Diana Mandelker f , Zsofia K. Stadler b,e,i , Eugene Pietzak a , Behfar Ehdaie a , Karim A. Touijer a , Vincent P. Laudone a , Susan F. Slovin b , Karen A. Autio b , Daniel C. Danila b , Dana E. Rathkopf b , James A. Eastham a , Yu Chen b , Michael J. Morris b , Kenneth Offit b,e , David B. Solit b,c , Howard I. Scher b , Wassim Abida b , Mark E. Robson b,e , Maria I. Carlo
doi : 10.1016/j.eururo.2022.08.028
Volume 83, Issue 1, January 2023, Pages 29-38
Prostate Cancer Genomic Testing: When Sequencing Is Not Sufficient and Germline Testing Is Necessary
Michelle F. Jacobs a,*, Samantha E. Greenberg
doi : 10.1016/j.eururo.2022.09.016
Volume 83, Issue 1, January 2023, Pages 39-40
Application of Improved Robot-assisted Laparoscopic Telesurgery with 5G Technology in Urology
Jianmin Li a,b,y, Xuecheng Yang b,y, Guangdi Chu b,y, Wei Feng c , Xuemei Ding d , Xulong Yin e , Liangjun Zhang f , Wei Lv g , Lufei Ma h , Liguo Sun h , Run Feng i , Jun Qin j , Xuefeng Zhang k , Chengyi Gou l , Zongyi Yu m , Bin Wei n , Wei Jiao b , Yonghua Wang b , Lei Luo b , Hang Yuan b , Yuan Chang o , Qiliang Cai p,*, Shuxin Wang a,*, Pier Cristoforo Giulianotti q,*, Qian Dong r,*, Haitao Niu
doi : 10.1016/j.eururo.2022.06.018
Volume 83, Issue 1, January 2023, Pages 41-44
Long-distance Robot-assisted Teleoperation: Every Millisecond Counts
Alessandro Larcher a,b,*, Federico Belladelli a,b , Umberto Capitanio a,b , Francesco Montorsi
doi : 10.1016/j.eururo.2022.09.032
Volume 83, Issue 1, January 2023, Pages 45-47
Prostate-Specific Antigen Screening in Transgender Patients
Farnoosh Nik-Ahd a,* ,y, Andrew Jarjour b,y, Jane Figueiredo c , Jennifer T. Anger d , Maurice Garcia e , Peter R. Carroll a , Matthew R. Cooperberg a , Adriana C. Vidal c , Stephen J. Freedland
doi : 10.1016/j.eururo.2022.09.007
Volume 83, Issue 1, January 2023, Pages 48-54
Approximately 0.4–1.3% of the worldwide population is transgender. Although the exact prevalence is unknown, there is an increase in open identification as transgender.
Efficacy of Laparoscopic Management of Posterior Urethral Diverticulum in Anorectal Malformations
Mei Diao a , Long Li a,b,*, An-Xiao Ming a , Chang-Zhen Yang a , Xiang-Hui Xie c,*, Wei Cheng
doi : 10.1016/j.eururo.2022.08.014
Volume 83, Issue 1, January 2023, Pages 55-61
A posterior urethral diverticulum (PUD) is a serious postoperative complication after anorectal malformation correction. Complete resection is technical demanding because of limited retrourethral working space deep in the pelvis.
Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen–radioguided Surgery
Sophie Knipper a,*,1, Mehrdad Mehdi Irai a,1, Ricarda Simon b , Daniel Koehler c , Isabel Rauscher d , Matthias Eiber d , Fijs W.B. van Leeuwen e , Pim van Leeuwen f , Hilda de Barros f , Henk van der Poel f , Lars Buda ̈us a , Thomas Steuber a,g , Markus Graefen a , Pierre Tennstedt a , Matthias M. Heck b , Thomas Horn b,2, Tobias Maurer
doi : 10.1016/j.eururo.2022.05.031
Volume 83, Issue 1, January 2023, Pages 62-69
In a subset of patients with recurrent oligometastatic prostate cancer (PCa) salvage surgery with prostate-specific membrane antigen (PSMA)-targeted radioguidance (PSMA-RGS) might be of value.
FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias
Ming-Jun Shi a,b,c,y, Jacqueline Fontugne b,c,d,e,y, Aura Moreno-Vega b,c,y, Xiang-Yu Meng b,c,f,y, Clarice Groeneveld b,g,y, Florent Dufour b,c,h , Aure �lie Kamoun g , Sia Viborg Lindskrog i , Luc Cabel b,c , Cle �mentine Krucker b,c , Audrey Rapinat j , Claire Dunois-Larde b,c , May-Linda Lepage b,c , Elodie Chapeaublanc b,c , Olivier Levrel k , Victoria Dixon b,e , Thierry Lebret l , Anna Almeida j , Aure �lien De Reynies g , Natacha Rochel m,n,o,p , Lars Dyrskjøt i , Yves Allory b,d,e , Franc ̧ ois Radvanyi b,c , Isabelle Bernard-Pierrot
doi : 10.1016/j.eururo.2022.09.030
Volume 83, Issue 1, January 2023, Pages 70-81
Bladder cancer (BCa) is more common in men and presents differences in molecular subtypes based on sex. Fibroblast growth factor receptor 3 (FGFR3) mutations are enriched in the luminal papillary muscle-invasive BCa (MIBC) and non-MIBC subtypes.
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial
Francesca Vignani a , Rosa Tambaro b , Ugo De Giorgi c , Patrizia Giannatempo d , Davide Bimbatti e , Claudia Carella f , Marco Stellato g , Francesco Atzori h , Michele Aieta i , Cristina Masini j , Alketa Hamzaj k , Paola Ermacora l , Antonello Veccia m , Giuseppa Scandurra n , Teresa Gamba a , Gianluca Ignazzi a , Sandro Pignata b , Marilena Di Napoli b , Cristian Lolli c , Giuseppe Procopio d , Francesco Pierantoni o , Antonia Zonno f , Daniele Santini g , Massimo Di Maio a,*, on behalf of Meet-URO12 Investigators
doi : 10.1016/j.eururo.2022.09.025
Volume 83, Issue 1, January 2023, Pages 82-89
Platinum-based chemotherapy (PBCT) is the standard first-line treatment for advanced urothelial carcinoma (UC). Potential cross-sensitivity can be hypothesized between platinum drugs and poly-ADP ribose-polymerase (PARP) inhibitors.
Re. Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial
Arnulf Stenzl
doi : 10.1016/j.eururo.2022.09.029
Volume 83, Issue 1, January 2023, Pages 90-91
Re: Neoadjuvant PD-L1 plus CTLA-4 Blockade in Patients with Cisplatin-ineligible Operable High-risk Urothelial Carcinoma
Sarah M.H. Einerhand a Jeroen van Dorp b,c Michiel S. van der Heijden b,c Bas W.G. van Rhijn
doi : 10.1016/j.eururo.2022.09.024
Volume 83, Issue 1, January 2023, Pages 91-92
Re: Management, Surveillance Patterns, and Costs Associated with Low-grade Papillary Stage Ta Non–muscle-invasive Bladder Cancer Among Older Adults, 2004–2013
Alexandre R. Zlotta
doi : 10.1016/j.eururo.2022.10.002
Volume 83, Issue 1, January 2023, Pages 92-93
Re: Removal of Small, Asymptomatic Kidney Stones and Incidence of Relapse
Christian Seitz * Zejlko Kikic
doi : 10.1016/j.eururo.2022.10.003
Volume 83, Issue 1, January 2023, Page 93
Re: Removal of Small, Asymptomatic Kidney Stones and Incidence of Relapse
Meng Gao Zhiyong Chen * Jinbo Chen
doi : 10.1016/j.eururo.2022.10.014
Volume 83, Issue 1, January 2023, Page 94
Re: Hilda A. de Barros, Matthias N. van Oosterom, Maarten L. Donswijk, et al. Robot-assisted Prostate-specific Membrane Antigen–radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study. Eur Urol 2022;82:97–105
Xiangyang Yao a Chen Duan b Bo Li b Xiaoliang Wu b Hua Xu
doi : 10.1016/j.eururo.2022.09.034
Volume 83, Issue 1, January 2023, Pages e11-e12
Reply to Xiangyang Yao, Chen Duan, Bo Li, Xiaoliang Wu and Hua Xu’s Letter to the Editor Re: Hilda A. de Barros, Matthias N. van Oosterom, Maarten L. Donswijk, et al. Robot-assisted Prostate-specific Membrane Antigen–radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study. Eur Urol 2022;82:97–105
Hilda A. de Barros a,b,* Matthias N. van Oosterom a,c Maarten L. Donswijk d Jeroen J.M.A. Hendrikx d,e André N. Vis b,f Tobias Maurer g,h Fijs W.B. van Leeuwen a,c Henk G. van der Poel a,b,f Pim J. van Leeuwen
doi : 10.1016/j.eururo.2022.10.008
Volume 83, Issue 1, January 2023, Pages e13-e14
Re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022:82:469–82.
Yongbao Wei a,b,* Haijian Huang c Liefu Ye
doi : 10.1016/j.eururo.2022.08.040
Volume 83, Issue 1, January 2023, Page e15
Reply to Yongbao Wei, Haijian Huang, and Liefu Ye’s Letter to the Editor re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82:469–82.
Mark A. Rubin a Mahul B. Amin b,c Eva Compérat d Anthony Gill e,f,g Arndt Hartman h Santosh Menon i Maria Raspollini j John Srigley k Puay Hoon Tan l Satish Ticktoo m Toyonori Tsuzuki n Samra Turajlic o Ian Cree p Daniel Berney q,r Holger Moch s George J. Netto
doi : 10.1016/j.eururo.2022.09.021
Volume 83, Issue 1, January 2023, Pages e16-e17
Re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?
Alireza Ghoreifi Hooman Djaladat
doi : 10.1016/j.eururo.2022.08.039
Volume 83, Issue 1, January 2023, Pages e18-e19
Reply to Alireza Ghoreifi and Hooman Djaladat’s Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?
Isamu Tachibana a,* Sean Q. Kern a Antoin Douglawi a Yan Tong b Mohammad Mahmoud a Timothy A. Masterson a Nabil Adra c Richard S. Foster a Lawrence H. Einhorn c Clint Cary
doi : 10.1016/j.eururo.2022.09.018
Volume 83, Issue 1, January 2023, Pages e20-e21
Reply to Minxiong Hu and Liefu Ye’s Letter to the Editor re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022;82:551–58
Ethan L. Ferguson Jihad H. Kaouk
doi : 10.1016/j.eururo.2022.10.011
Volume 83, Issue 1, January 2023, Pages e22-e23
Re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022;82:551–58
Shangqing Ren a Xu Hu b Kai Wang c Qian Lv a Dong Wang
doi : 10.1016/j.eururo.2022.09.033
Volume 83, Issue 1, January 2023, Pages e24-e25
Reply to Shangqing Ren, Xu Hu, Kai Wang, Qian Lv, and Wang Dong’s Letter to the Editor re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022;82:551–58
Ethan L. Ferguson Jihad H. Kaouk
doi : 10.1016/j.eururo.2022.10.007
Volume 83, Issue 1, January 2023, Pages e26-e27
Reply to Hela Sassi, Olivier Caron, and Etienne Rouleau’s Letter to the Editor re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243–50
Kara N. Maxwell a,b Colin C. Pritchard
doi : 10.1016/j.eururo.2022.09.022
Volume 83, Issue 1, January 2023, Page e28
Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Wei Shen Tan a,b,* John D. Kelly
doi : 10.1016/j.eururo.2022.10.009
Volume 83, Issue 1, January 2023, Pages e29-e30
Re: Giorgio Gandaglia, Elio Mazzone, Armando Stabile, et al. Prostate-specific Membrane Antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study. Eur Urol.2022;82:411–18
Bingzhi Wang Chao Li Xiaoping Zheng Kun Yao Long Wang
doi : 10.1016/j.eururo.2022.09.020
Volume 83, Issue 1, January 2023, Pages e31-e32
Congress Calendar
doi : 10.1016/j.eururo.2022.11.003
Volume 83, Issue 1, January 2023, Pages e33-e34
